A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorOstolin, Thais Lopes Valentim Di Paschoale-
Autor(es): dc.creatorGusmão, Miriã Rodrigues-
Autor(es): dc.creatorMathias, Fernando Augusto Siqueira-
Autor(es): dc.creatorCardoso, Jamille Mirelle de Oliveira-
Autor(es): dc.creatorRoatt, Bruno Mendes-
Autor(es): dc.creatorSoares, Rodrigo Dian de Oliveira Aguiar-
Autor(es): dc.creatorRuiz, Jeronimo Conceição-
Autor(es): dc.creatorResende, Daniela de Melo-
Autor(es): dc.creatorBrito, Rory Cristiane Fortes de-
Autor(es): dc.creatorReis, Alexandre Barbosa-
Data de aceite: dc.date.accessioned2025-08-21T15:55:11Z-
Data de disponibilização: dc.date.available2025-08-21T15:55:11Z-
Data de envio: dc.date.issued2021-09-03-
Data de envio: dc.date.issued2021-09-03-
Data de envio: dc.date.issued2020-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/jspui/handle/123456789/13648-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0264410X21004291?via%3Dihub-
Fonte completa do material: dc.identifierhttps://doi.org/10.1016/j.vaccine.2021.04.004-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1027461-
Descrição: dc.descriptionIn Brazil, canine visceral leishmaniasis is an important public health problem due to its alarming growth. The high prevalence of infected dogs reinforces the need for a vaccine for use in prophylactic vaccination campaigns. In the present study, we evaluate the immunogenicity and protection of the best dose of Chimera A selected through the screening of cytokines production important in disease. BALB/c mice were vaccinated subcutaneously with three doses and challenged intravenously with 1 107 L. infantum promastigotes. Spleen samples were collected to assess the intracellular cytokine profile production, T cell proliferation and parasite load. At first, three different doses of Chimera A (5 lg, 10 lg and 20 lg) were evaluated through the production of IFN-c and IL-10 cytokines. Since the dose of 20 lg showed the best results, it was chosen to continue the study. Secondarily, Chimera A at dose of 20 lg was formulated with Saponin plus Monophosphoryl lipid A. Vaccination with Chimera A alone and formulated with SM adjuvant system was able to increase the percentage of the proliferation of specific T lymphocytes and stimulated a Th1 response with increased levels of IFN-c, TNF-a and IL-2, and decreased of IL-4 and IL-10. The vaccine efficacy through real-time PCR demonstrated a reduction in the splenic parasite load in animals that received Chimera A formulated with the SM adjuvant system (92%). Additionally, we observed increased levels of nitric oxide in stimulated-culture supernatants. The Chimera A formulated with the SM adjuvant system was potentially immunogenic, being able to induce immunoprotective mechanisms and reduce parasite load. Therefore, the use of T-cell multi-epitope vaccine is promising against visceral leishmaniasis.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Palavras-chave: dc.subjectLeishmania infantum-
Palavras-chave: dc.subjectMulti-epitope vaccine-
Palavras-chave: dc.subjectImmune response-
Título: dc.titleA chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.